IPCALAB

Ipca Laboratories Ltd shares surged up to 12% on 17 August 2026,

Ipca Laboratories Ltd shares surged up to 12% on 17 August 2026, hitting a record high of ₹1,945 after reporting a 72% jump in quarterly profit and upgrading FY27 growth guidance. Brokerages including JM Financial, Nuvama, and Prabhudas Lilladher raised their target prices to ₹2,000–₹2,118, maintaining a ‘Buy’ rating. 📊 Q1 FY27 Financial Highlights Metric Q1 FY27 (June 2026) YoY Change Notes Revenue ₹ 2,788.10 crore +21% Strong domestic & export growth EBITDA ₹ 637.94 crore +50% Margin expanded 600 bps to 24% Net Profit (PAT) ₹ 401.89 crore +72% Driven by branded formulations & API EPS ₹ 15.84 +72% Analysts expected ₹ 12.43 — beat estimates Domestic formulations grew 13% YoY, branded generics 16%, and API exports 33%. The institutional export business doubled to ₹ 120 crore, though ₹ 40 crore was deferred from March shipments. 📈 Guidance & Outlook Revenue growth FY27: Raised to 14–16% (from 12–13%). EBITDA margin FY27: Upgraded to 23% (from 22%). US growth: Expected 15–17% with 7–8 new launches via Unichem subsidiary. FY29 target: Consolidated EBITDA margin 25–26%. Valuation: Trading at ~25× FY28E P/E; brokerages see scope for further re‑rating. 🧪 Segment Performance India Business: ₹ 1,082 crore revenue (+13% YoY). Export Business: Up 34% YoY; Europe grew ~70%. API Segment: Strong recovery in both domestic and export markets. Unichem Laboratories: Maintains 10% growth guidance and 13% EBITDA margin. 💹 Brokerage Ratings (17 Aug 2026) Brokerage Rating Target Price Key Comment JM Financial Buy ₹ 2,118 “Margins set to improve to 25–26% mid‑term.” Nuvama Institutional Equities Buy ₹ 2,025 “Strong mix change and operating leverage to drive profitability.” Prabhudas Lilladher Buy ₹ 2,000 “Recovery in API segment and steady domestic growth support valuation.”